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INTRODUCTION
The majority of  fast inhibitory neurotransmissions in the central nervous system (CNS) 
is governed by the action of  γ-aminobutyric acid (GABA) type A receptors (GABA-A). 
The complex structure and function of  GABA-A receptors and benzodiazepine binding 
sites was recently elucidated [1]. GABA-A receptors are pentameric membrane proteins 
that operate as GABA-gated Cl- channels. The majority contains a benzodiazepine 
binding site located at the interface of  the γ2-subunit and the respective α-subunit (α1, 
α2, α3, α5) [2].
At these receptors, there are several modulatory sites, which mediate the actions of  
many drugs, among them benzodiazepines [2]. Three kinds of  allosteric modulators 
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Research article
It has been shown in electrophysiological studies that the ligand L-655,708 possesses a 
binding selectivity and a moderate inverse agonist functional selectivity for α5-containing 
GABA-A receptors. The present study is aimed to investigate the antidepressant effects 
of  the ligand L-655,708 in the forced swim test (FST) and its impact on locomotor 
activity in rats.  The behavior of  the animals was recorded with a digital camera, and the 
data were analyzed by one-way ANOVA, followed by Dunnett’s test. In FST, L-655,708 
signifi cantly decreased immobility time at a dose of  3 mg/kg after a single and 
repeated administration (p<0.05), exerting acute and chronic antidepressant effects. 
However, it did not induce signifi cant differences in the time of  struggling behavior 
during FST. Furthermore, L-655,708 did not show a signifi cant effect on locomotor 
activity (p>0.05). These data suggest that negative modulation at GABA-A receptors 
containing the α5 subunit may produce antidepressant effects in rats. These effects 
were not confounded by locomotor infl uences.




act through the benzodiazepine binding site: positive (agonist), neutral (antagonist), 
and negative (inverse agonist) modulators [3]. It is established that agonists at the 
benzodiazepine site present anxiolytic and amnesic properties, whereas inverse agonists 
could exert opposite actions [4,5]. 
Recent genetic studies with mice carrying a point mutation in α1, α2, α3 or α5 subunits 
have suggested a specifi c contribution of  individual receptor subtypes to the spectrum 
of  behavioral actions of  these compounds [6]. These genetic advances have encouraged 
the synthesis and testing of  new, selective BZ site ligands, that possess stronger affi nity 
and/or effi cacy profi les [7]. Here, we focus on α5-containing GABA-A receptors, as 
these receptors are highly expressed in brain regions substantially involved in memory 
formation and emotion [8-10]. Previous evidence from animal studies has shown that 
the α5-containing GABA-A receptors were signifi cantly involved in cognition [11-14]. 
Moreover, it has been shown that a negative modulation of  α5 GABA-A receptors 
may represent an attractive treatment option for cognitive impairments, and potentially 
positive symptoms, associated with schizophrenia [15].
The goal of  the present study was to examine the infl uence of  the inverse agonist 
11,12,13,13a-tetrahydro-7-methoxy-9 oxo-9H-imidazo [1,5-a]pyrrolo[2,1-c] [1,4] 
benzodiazepine -1-carboxylic acid, ethyl ester (L-655,708), previously characterized by 
Atack et al. [11], acting on α5-subunit-containing GABA-A receptor and compare its 





Experiments were carried out on male Wistar rats (Military Farm, Belgrade, Serbia) 
weighing 180–230 g. The rats were housed in transparent plastic cages, six animals 
per cage, and had free access to pelleted food and tap water before and after drug 
administration. The animals were placed in a room kept at a temperature of  22 ± 1 
°C, relative humidity 40–70%, and 12/12-h light/dark period (lights on at 0630 h). All 
handling and testing took place during the light portion of  the cycle. The animals (6 
rats per treatment group) had been used only once throughout our study, after they 
were used in other trials. All procedures in the study were confi rmed to EEC Directive 
86/609 and approved by the Ethical Committee on Animal Experimentation of  the 
Medical Faculty in Belgrade.
 
Drugs
L-655,708, the inverse agonist selective for α5 GABAA receptors, was obtained from 
Sigma-Aldrich (Poole, Dorset, UK). The substance was dissolved in a vehicle containing 
saline (80%) and dimethylsulphoxide (20% DMSO, from Sigma-Aldrich), and injected 
intraperitoneally in a volume of  1 ml/kg. 
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Forced swim test
The forced swimming test, described by Porsolt et al. [16], was performed in a glass 
cylinder, 45 cm high, 20 cm diameter fi lled with water up to a height of  30 cm, with 
a temperature of  21-23 °C. Male Wistar rats were exposed to two swimming sessions 
(an initial 15-min pretest session, followed 24 h later by a 5-min test session). Time 
of  administration and doses of  L-655,708 were chosen based on previous studies 
by Attack et al. [11]. The animals received i.p. 0.3, 1, and 3 mg/kg of  L-655,708 or 
saline, 30 min before the test session. The duration of  immobility (seconds) was scored 
during the 5-min test session and the rat was considered immobile whenever it fl oated 
passively in the water and only made movements necessary to keep its head above the 
water line. The time of  struggling (seconds) during the 5-min test session consists of  
explosive muscular movements against the apparatus wall, in an attempt to escape from 
the cylinder. After the test, the rat was removed from the tank, dried with a towel, and 
placed back in its home cage. The water in the swim tank was changed between rats.
In the experiment with the repeated drug application, on the fi rst day, male Wistar rats 
were forced to swim for 15 min (pretest session). The rats were removed and randomly 
divided into two treatment groups. Solvent or L-655,708 (3 mg/kg) were administered, 
intraperitoneally, once a day for 14 days. Rats were re-exposed to the FST, for a single 
5-min session, 24h after the last drug administration.
Spontaneous locomotor activity
The measurement of  spontaneous locomotor activity was performed in a clear Plexiglas 
box (40×25×35 cm), immediately after the application of  increasing doses of  L-655,708 
(0.3, 1, and 3 mg/kg) or solvent. Time of  administration and doses of  L-655,708 were 
chosen based on previous studies [11]. To asses the spontaneous locomotor activity, the 
total distance traveled under dim red light (20 lx), was monitored by a digital camera 
placed above the box, for a total of  30 min, without any habituation period. Recording 
ofanimal activity and processing data were conducted by computer software ANY-maze 
Video Tracking System (Stoelting Co., Wood Dale, IL, USA).
 
Statistical analysis
All numerical data presented in the fi gures were given as the mean ± S.E.M. An alpha 
level of  0.05 was used for all statistical tests. In the forced swim test, the behavior of  the 
animals was recorded by a digital camera, and data were analyzed by one-way ANOVA, 
followed by Dunnett’s test. Spontaneous locomotor activity behavior was recorded by a 
digital camera, analyzed by the ANY-maze software.
RESULTS
Forced swimming
In the forced swim test, during the test session, ANOVA indicated statistically signifi cant 
effects of  L-655,708 (F(3,20)=6.42, p<0.05). L-655,708 signifi cantly decreased 
immobility time at the highest applied dose of  3 mg/kg, exerted acute antidepressant-
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like effects (Figure 1). However, L-655,708 did not induce signifi cant differences in the 
time of  struggling behavior during the test (data not shown).
In the experiments with repeated administration, a signifi cant effect of  treatment 
(F(1,18) = 4.779, p < 0.05) has been described. The administration of  L-655,708, once a 
day for 14 days, signifi cantly decreased the immobility time in the FST, when compared 
with the solvent-treated group, confi rming antidepressant effects (Figure 2).
Spontaneous locomotor activity
Treatment with L-655,708 did not affect the total distance traveled by the animals 
during 30 min of  monitoring spontaneous locomotor activity (F(3,20)=2.59, p>0.05) 
(Figure 3). 
Figure 1. Effects of  L-655,708 (L: 0.3, 1, and 3 
mg/kg), on the immobility time of  the animals 
in the forced swim test. * p<0.05 compared to 
solvent group (S).
Number of  animals per treatment was 6.
Figure 2. Effects of  repeated application 
of  L-655,708 (L: 3 mg/kg), on the immo-
bility time of  rats in the forced swim test. 
* p<0.05 compared to solvent group (S).
Number of  animals per treatment was 6.
Figure 3. Effects of  control (S) and L-655,708 (L: 0.3, 1, 
and 3 mg/kg) on the total distance traveled in the locomotor 
activity assay.  Number of  animals per treatment was 6.
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DISCUSSION
It was recently recognized that drugs with antidepressant / mood-stabilizing effects 
signifi cantly alter GABAergic transmission [17,18]. Namely, modulation in GABA-
ergic inhibition has been proposed to play an important role in the pathophysiology 
of  depression [19-21]. Data from experimental models demonstrate that the forced 
swim test represents a reliable and valuable behavioral research model of  depression 
in rodents and also an important tool to study neurobiological mechanisms involved 
in antidepressant activity. The substances with antidepressant potential signifi cantly 
reduce the animals’ immobility time, which is considered as a reaction of  despair 
and depressiveness [22].   In our study, decreased immobility was clearly observed 
with L-655,708 (3 mg/kg), after single and repeated administration, which shows its 
antidepressant-like properties. Furthermore, there was no effect on struggling time, 
confi rming that these effects were not confounded by change in motor function. 
L-655,708 possesses in vitro binding selectivity, as well as moderate inverse agonist 
functional selectivity for the α5-containing GABA-A receptors [11]. Receptors 
containing the α5 subunit constitute a modest fraction of  BZ-sensitive GABA-A 
receptors (approximately 5%), but are substantially expressed in several brain regions, 
most notably the hippocampus, the olfactory bulb and layers V and VI of  the neocortex 
[9,10]. Studies with untreated mice with the point mutation at the α5 subunit have 
indicated the signifi cance of  the α5 subunit for  learning certain aversively-motivated 
memory tasks which require temporal integration [23,24]. Our data suggest that negative 
modulation at GABA-A receptors containing the α5 subunit might have produced the 
antidepressant effects in rats and that these effects were not confounded by locomotor 
infl uences. 
Recent animal studies with the inverse agonist selective for α5 GABA-A receptors found 
improved learning and memory function in models of  cognitive defect, suggesting 
distinctive roles of  different subunits [25]. The antidepressant and memory-enhancing 
effects are in agreement with observations that low mood is frequently combined with 
anxiety and cognitive impairment [26]. A recently found correlation between helpless 
behavior and cognition [26,27] was fully supported by our results demonstrating that 
the antidepresant-like effect was obtained by the same selective agent (L-655,708) that 
previously induced memory-enhancing effects. The overall effect of  L-655,708 may thus 
refl ect a better performance based on both cognition and motivational enhancements.
The results of  our study are consistent with previously published data, which demonstrate 
a role for GABA-A receptors in depressive-like behavior [20, 21, 28, 29]. However, 
while α2-containing GABA-A receptors are known to be involved in regulating anxiety-
like behavior [30], our results suggest that α5-containing GABA-A receptors may be 
involved in depressive-like behavior. To the best of  our knowledge, our study is one 
of  the fi rst reports on the infl uence of  a benzodiazepine inverse agonist selective for 
α5-subunit-containing GABA-A receptors on rat behavior in forced swim test.  The 
observed action was antidepressant and, at fi rst glance, this seems to contradict the 
view that decreased GABA-A receptor activity enhances depression [17]. But, it should 
be taken into account, however, that such effects may occur at higher doses of  the 
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drug. The acute antidepressant effect of  GABA-A activation observed here, shows 
striking similarity to the effects of  glutamatergic NMDAR antagonists reported by 
other authors [31-33]. In these papers, the NMDAR antagonists, after only 30 min, 
signifi cantly reduced immobility in FST compared to vehicle-treated animals, suggesting 
that NMDAR blockade produces fast-acting antidepressant responses. Here we report 
a complementary acute antidepressant action by interfering with the counterbalancing, 
GABA-ergic system.  Similar actions were also found in humans [34]. 
In conclusion, our results experimentally support the fi nding that inverse agonists 
selective for α5 GABA-A receptors produce antidepressant effects, and these effects are 
not confounded by locomotor infl uences. The molecular substrates linking the actions 
of  specifi c GABA-benzodiazepine receptor subunits awaits to be further elucidated and 
linked to human neuropsychiatric disorders.
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ANTIDEPRESIVNI EFEKTI INVERZNOG AGONISTE SELEKTIVNOG 
ZA α5 GABA-A RECEPTORE U TESTU FORSIRANOG PLIVANJA 
PACOVA
SAMARDŽIĆ Janko, PUŠKAŠ Laslo, OBRADOVIĆ Miljana, LAZIĆ-PUŠKAŠ 
Dijana, OBRADOVIĆ I Dragan
U elektrofi ziološkim ispitivanjima pokazano je da ligand L-655,708 poseduje selektivnost 
u vezivanju i umerenu inverznu agonističku aktivnost za GABA-A receptore koji sadrže 
α5 podjedinicu. Ova studija ima za cilj ispitivanje antidepresivnih efekata liganda 
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L-655,708 u testu forsiranog plivanja (FST) i njegov uticaj na lokomotornu aktivnost 
kod pacova. Ponašanje životinja je praćeno pomoću digitalne kamere, a podaci su 
analizirani primenom jednostepene analize varijanse (ANOVA) i Dunett-ovim testom. 
U testu forsiranog plivanja L-655,708 statistički značajno smanjuje vreme imobilnosti 
pri dozi od 3 mg/kg, nakon jednokratne i ponavljane primene (p<0,05), ispoljavajući 
akutne i hronične antidepresivne efekte. Međutim, nije uticao značajno na vreme 
provedeno u borbi za preživljavanje tokom FST. Osim toga, L-655,708 nije pokazao 
značajan uticaj na lokomotornu aktivnost (p>0,05). Ovi podaci ukazuju da negativna 
modulacija GABA-A receptora koji sadrže α5 podjedinicu može ispoljiti antidepresivne 
efekte kod pacova. Ovi efekti su bez izraženih lokomotornih uticaja.
